![Donald McCaffrey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 1 M $ in data 31/05/2026
Mr. Donald J.
McCaffrey is a Chairman, President & Chief Executive Officer at Zenith Capital Corp.
(Alberta) and a Chairman, President, CEO & Secretary at Resverlogix Corp.
Mr. McCaffrey also served on the board at Stem Cell Therapeutics Corp.
and ProMIS Neurosciences, Inc.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 31/03/2026 | 7.027.513 ( 4,4% ) | 702 751 $ | 31/01/2026 | |
RESVERLOGIX CORP. 1,53% | 02/01/2026 | 5.263.266 ( 1,53% ) | 384 218 $ | 31/05/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| RESVERLOGIX CORP. | Amministratore Delegato | 25/04/2003 |
| ZENITH CAPITAL CORP. | Amministratore Delegato | 10/04/2013 |
| Società | Posizione | Fine |
|---|---|---|
| TRILLIUM THERAPEUTICS | Direttore/Membro del Consiglio | 27/03/2006 |
| PROMIS NEUROSCIENCES, INC. | Direttore/Membro del Consiglio | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 4 |
|---|---|
Resverlogix Corp.
 Resverlogix Corp. Pharmaceuticals: MajorHealth Technology Engages in the research and development of novel biopharmaceuticals for the treatment of grievous diseases | Health Technology |
Trillium Therapeutics, Inc.
 Trillium Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Researches, develops and manufactures medicines & therapies for cancer | Health Technology |
Zenith Capital Corp. (Alberta)
 Zenith Capital Corp. (Alberta) BiotechnologyHealth Technology Engages in the research and development of biopharmaceuticals | Health Technology |
ProMIS Neurosciences, Inc.
 ProMIS Neurosciences, Inc. BiotechnologyHealth Technology Discovers and develops precision medicine solutions for the treatment of neurodegenerative & misfolded protein diseases | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
